Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians
Annals of Internal MedicinePublished 18 November 2008
Gerald Gartlehner, Bradley N. Gaynes, Richard A. Hansen, Patricia Thieda, Angela DeVeaugh‐Geiss, Erin E. Krebs
Citations235
SJR quartileQ1
SJR score3.38
SNIP3.27
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
This is the first meta-analysis of second-generation antidepressants to assess quantitatively all possible comparisons among drugs in this class and to determine whether efficacy, effectiveness, and harms differed among subgroups of patients on the basis of age, sex, race or ethnicity, or comorbid conditions.
Abstract
Current evidence does not warrant the choice of one second-generation antidepressant over another on the basis of differences in efficacy and effectiveness. Other differences with respect to onset of action and adverse events may be relevant for the choice of a medication.
Keywords
PsychologyMedicine
Archives of General PsychiatryLifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication
20,497 Citations2005Ronald C. Kessler, Patricia A. Berglund +4 more
Lifetime prevalence estimates are higher in recent cohorts than in earlier cohorts and have fairly stable intercohort differences across the life course that vary in substantively plausible ways among sociodemographic subgroups.
American Journal of PsychiatryAcute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
5,538 Citations2006A. John Rush, Madhukar H. Trivedi +14 more
The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Medical CareInterpretation of Changes in Health-related Quality of Life
4,613 Citations2003Geoffrey R. Norman, Jeff A. Sloan +1 more
In most circumstances, the threshold of discrimination for changes in health-related quality of life for chronic diseases appears to be approximately half a SD, which research in psychology has shown is approximately 1 part in 7.
Health Technology AssessmentEvaluating non-randomised intervention studies
2,926 Citations2003Jonathan J Deeks, Jacqueline Dinnes +6 more
The inability of case-mix adjustment methods to compensate for selection bias and the inability to identify non- randomised studies that are free of selection bias indicate that non-randomised studies should only be undertaken when RCTs are infeasible or unethical.
American Journal of Preventive MedicineCurrent methods of the U.S. Preventive Services Task Force
1,734 Citations2001Russell Harris, Mark Helfand +5 more
This paper summarizes the current methods of the third USPSTF, supported by the Agency for Healthcare Research and Quality and two of the AHRQ Evidence-based Practice Centers (EPCs), and examines a variety of methodologic issues and document work group progress in future communications.
JAMASertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina
1,409 Citations2002Alexander H. Glassman
The Journal of Clinical PsychiatryThe Economic Burden of Depression in the United States
1,283 Citations2003RN, Ronald C. Kessler +5 more
The economic burden of depression remained relatively stable between 1990 and 2000, despite a dramatic increase in the proportion of depression sufferers who received treatment.
CHEST JournalGrading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
1,214 Citations2006Gordon Guyatt, David D. Gutterman +7 more
An American College of Chest Physicians task force formulated the criteria for a grading system to be utilized in all ACCP guidelines that included simplicity and transparency, explicitness of methodology, and consistency with current methodological approaches to the grading process.
Statistics in MedicineNetwork meta‐analysis for indirect treatment comparisons
1,206 Citations2002Thomas Lumley
New England Journal of MedicineBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
1,049 Citations2006A. John Rush, Madhukar H. Trivedi +11 more
After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant, suggesting any one of the medications in the study provided a reasonable second-step choice for patients with depression.
The British Journal of PsychiatryRemission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
805 Citations2001Michael E. Thase, A.R. Entsuah +1 more
Remission rates were significantly higher with venlafaxine than with an SSRI and the difference between SSRIs and placebo reached significance at week 4, and were not dependent on any one study or the definition of remission.
Health Technology AssessmentIndirect comparisons of competing interventions
678 Citations2005Anne‐Marie Glenny, Douglas G. Altman +6 more
There is a need to evaluate methods for the analysis of indirect comparisons for continuous data and for empirical research into how different methods of indirect comparison perform in cases where there is a large treatment effect.
JAMAAntidepressants and the Risk of Suicidal Behaviors
578 Citations2004Hershel Jick
It is concluded that there is no substantial difference in effect of the 4 drugs on people aged 10 to 19 years, and the risk of suicidal behavior after starting antidepressant treatment is similar among users of amitriptyline, fluoxetine, and parxetine compared with the risk among users with a recorded diagnosis of first-time nonfatal suicidal behavior.
Biological PsychiatrySelective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
558 Citations1998Jerrold F. Rosenbaum, Maurizio Fava +3 more
Abrupt interruption of antidepressant therapy for 5-8 days was associated with the emergence of new somatic and psychological symptoms in patients treated with paroxetine and to a lesser degree sertraline, with few symptoms seen with fluoxetines.
The Journal of Clinical PsychiatryPrevalence of Sexual Dysfunction Among Newer Antidepressants
539 Citations2002Anita H. Clayton, James F. Pradko +8 more
This is the first study to assess sexual dysfunction across the newer antidepressants using consistent methodology and a validated rating scale and overall, SSRIs and venlafaxine XR were associated with higher rates of sexual dysfunction than bupropion or nefazodone.
BMJAssociation between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials
507 Citations2005Dean Fergusson, Steve Doucette +5 more
The authors' systematic review, which included a total of 87 650 patients, documented an association between suicide attempts and the use of SSRIs.
JAMAEffect of Hypericum perforatum (St John's Wort) in Major Depressive Disorder
479 Citations2002Hypericum Depression Trial Study Group
New England Journal of MedicineMaintenance Treatment of Major Depression in Old Age
478 Citations2006Charles F. Reynolds, Mary Amanda Dew +16 more
Patients 70 years of age or older with major depression who had a response to initial treatment with paroxetine and psychotherapy were less likely to have recurrent depression if they received two years of maintenance therapy with parxetine, and monthly maintenance psychotherapy did not prevent recurrent depression.
Incidence of Sexual Dysfunction Associated With Antidepressant Agents: A Prospective Multicenter Study of 1022 Outpatients
477 Citations2001Ángel L. Montejo, Ginés Llorca +1 more
JAMATreatment of Dysthymia and Minor Depression in Primary Care
464 Citations2000John W Williams, Jane Barrett +6 more
Paroxetine showed moderate benefit for depressive symptoms and mental health function in elderly patients with dysthymia and more severely impaired elderly Patients with minor depression.
PubMedIncidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
464 Citations2001Ángel L. Montejo, Ginés Llorca +2 more
The incidence of sexual dysfunction with SSRIs and venlafaxine is high, ranging from 58% to 73%, as compared with serotonin-2 (5-HT2) blockers (nefazodone and mirtazapine), moclobemide, and amineptine.
Annals of Internal MedicineA Systematic Review of Newer Pharmacotherapies for Depression in Adults: Evidence Report Summary: Clinical Guideline, Part 2
427 Citations2000John W Williams, Cynthia D. Mulrow +4 more
The goal was to summarize data on the efficacy of newer antidepressants and herbal treatments compared with placebo, older antidepressants, and each other for a broad spectrum of depressive disorders.
American Journal of PsychiatrySuicide Rates in Clinical Trials of SSRIs, Other Antidepressants, and Placebo: Analysis of FDA Reports
393 Citations2003Arif Khan, Shirin Khan +2 more
Findings fail to support either an overall difference in suicide risk between antidepressant- and placebo-treated depressed subjects in controlled trials or a difference between SSRIs and either other types of antidepressants or placebo.
Archives of General PsychiatryTreating Depression in Alzheimer Disease
389 Citations2003Constantine G. Lyketsos, Lourdes DelCampo +9 more
Sertraline is superior to placebo for the treatment of major depression in Alzheimer disease and depression reduction is accompanied by lessened behavior disturbance and improved activities of daily living, but not improved cognition.
BMJSelective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review
385 Citations2005David Gunnell, Julia Saperia +1 more
No evidence that SSRIs increased the risk of suicide is found, but important protective or hazardous effects cannot be excluded, and larger trials with longer follow up are required to assess the balance of risks and benefits fully.
The Journal of Clinical PsychiatryDuloxetine, 60 mg Once Daily, for Major Depressive Disorder
383 Citations2002Michael J. Detke, Yili Lu +3 more
Duloxetine, 60 mg/day, is a well-tolerated and effective treatment for MDD that reduces painful physical symptoms and is suggested to be a first-line treatment for patients with MDD and associated painfulPhysical symptoms.
BMJFatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data
382 Citations2002Nicholas A. Buckley, Peter R McManus
The relative frequency with which venlafaxine and other new antidepressants result in fatal poisoning is established, to establish the relative frequency of the use of newer serotoninergic antidepressants.
BMJFluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
363 Citations1991Charles M. Beasley, Bruce E. Dornseif +7 more
Data from these trials do not show that fluoxetine is associated with an increased risk of suicidal acts or emergence of substantial suicidal thoughts among depressed patients.
Depression and AnxietyComparison of pramipexole, fluoxetine, and placebo in patients with major depression
359 Citations2000Mark H. Corrigan, Angelita Q. Denahan +3 more
Results indicated that by endpoint (week 8), patients receiving pramipexole at the 1.0 mg per day dose had significant improvement over baseline compared to the placebo group by measure of the HAM‐D, MADRS, and CGI‐SI.
The Journal of Clinical PsychiatryFixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed Outpatients
355 Citations2002W. J. Burke, I. Gergel +1 more
Escitalopram, a single isomer SSRI, is well-tolerated and has demonstrated antidepressant efficacy at a dose of 10 mg/day.
The Journal of Clinical PsychiatryDuloxetine in the Treatment of Major Depressive Disorder
335 Citations2002D. Goldstein, Craig Mallinckrodt +2 more
Duloxetine is efficacious for the treatment of major depressive disorder and is well tolerated and safe, and insomnia and asthenia were the only adverse events reported statistically significantly (p < .05) more frequently by duloxettine-treated patients compared with placebo- treated patients.
The Journal of Clinical PsychiatryEffects of Venlafaxine on Blood Pressure
327 Citations1998Michael E. Thase
Concern about blood pressure effects should not deter first-line use of this effective antidepressant, although more extensive studies of patients with cardiovascular diseases are still necessary.
JAMASimilar Effectiveness of Paroxetine, Fluoxetine, and Sertraline in Primary Care
317 Citations2001Kurt Kroenke, Suzanne L West +8 more
The SSRI antidepressants paroxetine, fluoxettine, and sertraline were similar in effectiveness for depressive symptoms as well as multiple domains of health-related quality of life over the entire 9 months of this trial.
Journal of Clinical PsychopharmacologyDuloxetine in the Treatment of Depression
316 Citations2004D. Goldstein, Yili Lu +4 more
Duloxetine therapy was efficacious for emotional and physical symptoms of depression, with a selective serotonin reuptake inhibitor-like profile of side effects.
International Clinical PsychopharmacologyA double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
300 Citations1994G. Clerc, P. Ruimy +1 more
European NeuropsychopharmacologyDuloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
283 Citations2004Michael J. Detke, Curtis G. Wiltse +4 more
These data support previous findings that duloxetine is safe, efficacious, and well tolerated in the acute treatment of major depressive disorder.
Journal of Psychiatric ResearchDuloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
279 Citations2002Michael J. Detke, Yili Lu +3 more
Duloxetine 60 mg administered once daily appears to be a safe and effective treatment for MDD.
PubMedAntidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression.
262 Citations1990Fred Reimherr, G Chouinard +6 more
The amitriptyline group showed a higher proportion of anticholinergic and sedative side effects and dizziness compared with patients who received either sertraline or placebo, and showed a significantly greater improvement from baseline than the placebo group.
Acta Psychiatrica ScandinavicaA controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
261 Citations1992Anna Lena Nyth, C. G. Gottfries +8 more
Results of ratings on the Gottfries‐Bråne‐Steen dementia rating scale indicated that both cognitive and emotional functioning improved significantly more in the citalopram‐ treated subgroup of patients with dementia than in the placebo‐treated subgroup.
The Journal of Clinical PsychiatryFluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder
258 Citations2000Maurizio Fava, Rajinder Judge +3 more
Risk of weight gain during extended SSRI treatment differs depending on which SSRI is used, and paroxetine-treated patients experienced a significant weight increase, and patients treated with sertraline had a modest but nonsignificant weight increase.
PubMedExploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder.
258 Citations2001R. Bruce Lydiard
Annals of Internal MedicineEfficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder
258 Citations2005Richard A. Hansen, Gerald Gartlehner +3 more
Psychosomatic MedicineEfficacy and Safety of Fluoxetine in the Treatment of Patients With Major Depression After First Myocardial Infarction: Findings From a Double-Blind, Placebo-Controlled Trial
255 Citations2000Werner Strik, Adriaan Honig +7 more
The results of this study suggest that fluoxetine can be safely used to treat patients with post-MI depression beginning 3 months after the event and was associated with a statistically significant reduction in hostility.
BMJAntidepressants and suicide
252 Citations1995Susan S. Jick, Alan D. Dean +1 more
Several factors correlate with the risk of suicide in people taking antidepressants, and rates of suicide were higher in patients who received fluoxetine, but this may be explained by selection biases which were present for those drug users.
The British Journal of PsychiatrySertraline in the Prevention of Depression
246 Citations1992D.P. Doogan, Vincent Caillard
The study provides evidence that sertraline prevents relapse of the index episode of depression as well as recurrence of further episodes and has few side-effects.
The Journal of Clinical PsychiatryOnce-Daily Venlafaxine Extended Release (XR) Compared With Fluoxetine in Outpatients With Depression and Anxiety
246 Citations1999Peter H. Silverstone, Arun Ravindran +1 more
Once-daily venlafaxine XR is effective and well tolerated for the treatment of major depression and concomitant anxiety and provides evidence for superiority over fluoxetine.
The Journal of Clinical PsychiatryResponse and Remission Rates in Different Subpopulations With Major Depressive Disorder Administered Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Placebo
245 Citations2001A.R. Entsuah, Holly Huang +1 more
It is suggested that men and women have comparable responses to SSRIs and venlafaxine across various age groups and patients exhibited a more rapid onset and a greater likelihood of remission with venl Lafaxine therapy than with SSRI therapy regardless of age or gender.
Clinical TherapeuticsA placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline
242 Citations1999Harry A. Croft, Edmund C. Settle +4 more
Bupropion SR may be an appropriate choice as an antidepressant for the treatment of sexually active patients and sertraline treatment was more often associated with sexual dysfunction and certain other adverse events compared with bupropion SR and placebo.
BMJAntidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study
241 Citations2005Carlos Martínez, Stephan Rietbrock +6 more
There is some weak evidence of an increased risk of non-fatal self harm for current SSRI use among those aged 18 or younger, but preferential prescribing of SSRIs to patients at higher risk of suicidal behaviour cannot be ruled out.
International Clinical PsychopharmacologyEscitalopram 10???mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care
234 Citations2002Alan Wade, Ole Lemming +1 more
International Clinical PsychopharmacologyEscitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care
225 Citations2003Ulla Lepola, Henrik Loft +1 more
Escitalopram 10 mg/day had a statistically significantly better antidepressant effect than placebo as early as week 1, and was safe and very well tolerated.
The Journal of Clinical PsychiatryAntidepressant-Induced Sexual Dysfunction During Treatment With Moclobemide, Paroxetine, Sertraline, and Venlafaxine
219 Citations2000Sidney H. Kennedy, Beata S. Eisfeld +3 more
An unexpected relationship was found between favorable drug response and a decreased level of drug-induced sexual dysfunction in patients treated with sertraline or paroxetine.
Biological PsychiatryComparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder
215 Citations1998A. John Rush, Roseanne Armitage +11 more
Nefazodone was associated with normal objective, and clinician- and patient-rated assessments of sleep when compared with fluoxetine, and these differential sleep EEG effects are consistent with the notion that nefzodone and fluoxettine may have somewhat different modes and spectra of action.
Journal of Clinical EpidemiologyA simple and valid tool distinguished efficacy from effectiveness studies
211 Citations2006Gerald Gartlehner, Richard A. Hansen +3 more
When applied in a standardized manner, the proposed criteria can provide a valid and simple tool to distinguish effectiveness from efficacy studies and can also be used to determine the external validity of individual studies, given an appropriate population of interest.
Archives of General PsychiatrySertraline for Prevention of Depression Recurrence in Diabetes Mellitus
204 Citations2006Patrick J. Lustman, Ray E. Clouse +8 more
In patients with diabetes, maintenance therapy with sertraline prolongs the depression-free interval following recovery from major depression and is associated with improvements in glycosylated hemoglobin levels for at least 1 year.
Journal of Women s HealthRelative Antidepressant Efficacy of Venlafaxine and SSRIs: Sex-Age Interactions
204 Citations2005Michael E. Thase, Richard Entsuah +2 more
Findings provide further evidence that age, gender, and HRT moderate response to antidepressant medications.
American Journal of PsychiatryOptimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment
203 Citations1998Frederick W. Reimherr, Jay D. Amsterdam +8 more
Relapse rates were lower among the patients who continued to take fluoxetine compared with those transferred to placebo in both the first interval, after 24 total weeks of treatment, and the second, after 38 total weeks, which were not significantly different between the groups.
International Clinical PsychopharmacologyPredictors of an acute antidepressant response to fluoxetine and sertraline
203 Citations1999M. F. Flament, Roger Lane +2 more
Archives of General PsychiatryA Placebo-Controlled, Randomized Clinical Trial Comparing Sertraline and Imipramine for the Treatment of Dysthymia
200 Citations1996Michael E. Thase
Pharmacotherapy provides considerable relief from the symptoms of dysthymia in patients suffering from this chronic affective disorder, with both sertraline and imipramine being more effective than placebo.
Breast Cancer Research and TreatmentEffect of paroxetine hydrochloride (Paxil�) on fatigue and depression in breast cancer patients receiving chemotherapy
198 Citations2005Joseph A. Roscoe, Gary R. Morrow +7 more
Results suggest that modulation of serotonin may not be a primary mechanism of fatigue related to cancer treatment, and administration of an antidepressant that alleviates symptoms of depression could also reduce fatigue.
American Journal of PsychiatryEmergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
198 Citations1997Maurizio Fava, Rosemarie Mulroy +3 more
The results suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medication dose gradually, and not immediately after discontinuation of treatment with the study drug.
American Journal of PsychiatryAntidepressant Pharmacotherapy in the Treatment of Depression in the Very Old: A Randomized, Placebo-Controlled Trial
191 Citations2004Steven P. Roose, Harold A. Sackeïm +7 more
In the oldest group of community-dwelling patients to be studied to date, medication was not more effective than placebo for the treatment of depression, however, given the considerable psychosocial support received by all patients, the placebo condition represents more than the ingestion of an inactive pill.
International Clinical PsychopharmacologyParoxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
190 Citations1993S.A. Montgomery, G. Dunbar
Paroxetine was effective in preventing the reappearance of depression following an acute illness and the benefit of long-term pharmacotherapy for treating depressive illness is confirmed.
International Clinical PsychopharmacologyProspective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder
188 Citations2005Nicholas Moore, Hélène Verdoux +1 more
A double-blind, randomized clinical trial was performed in which general practitioners and psychiatrists compared fixed doses of escitalopram with citaloprams over 8 weeks in outpatients with major depressive disorder (MDD) and confirmed that escITALopram has a superior effect in MDD.
American Journal of Geriatric PsychiatryDouble-Blind, Randomized Comparison of Mirtazapine and Paroxetine in Elderly Depressed Patients
187 Citations2002Alan F. Schatzberg, C.M.E. Kremer +2 more
During the first weeks of treatment, antidepressant effects were more pronounced in the mirtzapine group, suggesting that mirtazapine has an earlier onset of action.
PubMedNefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction.
186 Citations1996Alan D. Feiger, Ari Kiev +3 more
Nefazodone and sertraline are well tolerated, and there was no statistically significant difference in their antidepressant activity.
Biological PsychiatrySertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo
184 Citations1995Louis F. Fabre, F.S. Abuzzahab +6 more
The results of this study show that sertraline 50 mg once daily is as effective as higher dosages for the treatment of major depression with fewer side effects and therapy discontinuations.
JAMAMaintenance Phase Efficacy of Sertraline for Chronic Depression<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
184 Citations1998Martín Keller
Maintenance therapy with sertraline is well tolerated and has significant efficacy in preventing recurrence or reemergence of depression in chronically depressed patients.
PharmacopsychiatrySide-Effect Profile of Fluoxetine in Comparison with Other SSRIs, Tricyclic and Newer Antidepressants: A Meta-Analysis of Clinical Trial Data
182 Citations2005Paolo Brambilla, Andrea Cipriani +2 more
This paper presents a probabilistic procedure for estimating the total number of particles in the response of the immune cells of the central nervous system during the first trimester of pregnancy.
Clinical TherapeuticsA placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine
181 Citations2001C C Coleman
Bupropion SR may be an appropriate initial choice for the treatment of depression in patients concerned about sexual functioning and fluoxetine was more frequently associated with sexual dysfunction compared with bupropion SR.
The Journal of Clinical PsychiatryA Double-Blind Comparison of Escitalopram and Venlafaxine Extended Release in the Treatment of Major Depressive Disorder
181 Citations2004Robert J. Bielski, Daniel Ventura +1 more
Results of this study indicate that, when titrated rapidly to their maximum recommended doses, escitalopram is at least as effective as venlafaxine XR and significantly better tolerated and do not support the hypothesis that nonselective SRIs have greater efficacy than selective SRIs.
PubMedTreatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years.
181 Citations2001James E. Barrett, John W Williams +7 more
For dysthymia, paroxetine and PST-PC improved remission compared with placebo plus nonspecific clinical management; general clinical management (watchful waiting) is an appropriate treatment option.
Journal of Psychiatric ResearchDuloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder
180 Citations2004Stephen K. Brannan, Craig Mallinckrodt +4 more
Duloxetine (60 mg QD) was shown to be an effective treatment for the painful physical symptoms which are frequently associated with depression.
The Journal of Clinical PsychiatryA Prospective Safety Surveillance Study for Bupropion Sustained-Release in the Treatment of Depression
179 Citations1998David L. Dunner, Sidney Zisook +4 more
The therapeutic use of bupropion SR at total daily doses up to 300 mg/day in depressed patients without predisposition to seizures is associated with a seizure rate that is well within the range observed with other marketed antidepressants.
The British Journal of PsychiatryA Comparison of Paroxetine, Imipramine and Placebo in Depressed Out-patients
176 Citations1991G. C. Dunbar, Jay B. Cohn +5 more
Paroxetine had a possible earlier antidepressant effect than imipramine, and a possibleEarlier beneficial effect on anxiety symptoms associated with depression, according to pooled data from six centres using the same protocol.
The Journal of Clinical PsychiatryEarly Improvement Under Mirtazapine and Paroxetine Predicts Later Stable Response and Remission With High Sensitivity in Patients With Major Depression
175 Citations2003Armin Szegedi, Matthias J. Müller +4 more
The results strongly suggest that early improvement predicts later stable response with high sensitivity for both antidepressants tested and provide important clinical clues for an individually tailored antidepressant treatment.
PubMedAntidepressants and the serotonin syndrome in general practice.
172 Citations1999F. J. Mackay, Nicholas Dunn +1 more
Improved awareness of the serotonin syndrome is needed within general practice, and there is a need to distinguish the relatively minor serotonergic symptoms from those of a severe, life-threatening serotonin syndrome.
The British Journal of PsychiatryVenlafaxine and paroxetine in treatment-resistant depression
171 Citations1999Jillian R. Gregson
NeuropsychobiologyA Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder
170 Citations2004Stuart Montgomery, A.K.T. Huusom +1 more
Escitalopram treatment was similar to venlafaxine treatment with respect to efficacy and was better tolerated by patients in primary care and when treatment was completed after 8 weeks.
American Journal of PsychiatryChanges in Weight During a 1-Year Trial of Fluoxetine
169 Citations1999David Michelson, Jay D. Amsterdam +7 more
It is found that after remission of depressive symptoms, weight gain for patients taking fluoxetine for longer periods is not different from that for patientsTaking placebo and is most likely related to recovery from depression.
American Journal of PsychiatryAn 8-Week Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled Study of Sertraline in Elderly Outpatients With Major Depression
166 Citations2003Lon S. Schneider, J. Craig Nelson +6 more
Sertraline was effective and well tolerated by older adults with major depression, although the drug-placebo difference was not large in this 8-week trial.
The Journal of Clinical PsychiatryComparative Effects of Mirtazapine and Fluoxetine on Sleep Physiology Measures in Patients With Major Depression and Insomnia
165 Citations2003Andrew Winokur, Nicholas DeMartinis +4 more
These data demonstrate the differential effects of mirtazapine and fluoxetine, with significant improvement in favor of mIRTZapine, on objective sleep parameters in MDD patients with insomnia.
The Journal of Clinical PsychiatryMulticenter, Placebo-Controlled, Fixed-Dose Study of Citalopram in Moderate-to-Severe Depression
164 Citations1999John P. Feighner, K. Fredricson Overø
Citalopram was significantly more effective than placebo in the treatment of moderate-to-severe major depression, especially symptoms of depressed mood and melancholia, with particularly robust effects shown at doses of 40 and 60 mg/day.
The Journal of Clinical PsychiatryA Double-Blind Comparison of Sertraline and Fluoxetine in Depressed Elderly Outpatients
164 Citations2000Paul Newhouse, K. Ranga R. Krishnan +4 more
Data indicate that both drugs are effective antidepressants for the treatment of depressed elderly outpatients and differences in cognitive performance effects deserve further investigation.
Journal of Affective DisordersA double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
161 Citations1999Richard L. Rudolph, Alan D. Feiger
Venlafaxine XR is a well-tolerated and efficacious treatment for depression but may have some efficacy advantages over fluoxetine.
The Journal of Clinical PsychiatryMirtazapine Compared With Paroxetine in Major Depression
160 Citations2000Otto Benkert, Armin Szegedi +1 more
A potentially faster onset of overall therapeutic efficacy of mirtazapine was suggested by significant differences between treatments after 1 week of therapy that were due to slightly larger improvements of several core symptoms of depression as well as distinct prevention of treatment-emergent worsening of anxiety and physical components of depression.
Journal of Clinical PsychopharmacologyA Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression
159 Citations1994Lynn Cunningham, Richard L. Borison +6 more
Both active treatments were significantly more effective than placebo on some measures during the short-term study, but venlafaxine produced more improvement in the cognitive disturbance and retardation factors on the Hamilton Rating Scale for Depression.
Progress in Neuro-Psychopharmacology and Biological PsychiatryA double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
154 Citations1996Michel Dieric, Ujigi Ravizza +2 more
Venlafaxine 75 mg daily is comparable to fluoxetine, but at 150 mg daily, it may be superior to fluxetine in outpatients with major depression who do not respond early to treatment.
PubMedA 102-center prospective study of seizure in association with bupropion.
153 Citations1991Joseph A. Johnston, CHARLES G. LINEBERRY +5 more
These rates confirm earlier seizure estimates and fall within accepted parameters for antidepressant drugs, and enhances bupropion's position as a valuable alternative for the management of depression.
The Journal of Clinical PsychiatryDouble-Blind Comparison of Bupropion Sustained Release and Sertraline in Depressed Outpatients
150 Citations1997Richard J. Kavoussi, Robert Segraves +3 more
Both compounds were relatively well tolerated, and orgasm dysfunction, nausea, diarrhea, somnolence, and sweating were reported more frequently in sertraline-treated patients.
International Journal of Geriatric PsychiatryHyponatraemia in elderly psychiatric patients treated with Selective Serotonin Reuptake Inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit
147 Citations2002Dianne Kirby, Susan Harrigan +1 more
To determine the prevalence of hyponatraemia associated with selective serotonin reuptake inhibitor (SSRI) and venlafaxine use in elderly patients compared to that in elderly Patients not prescribed these drugs, while controlling for age, sex, depression status and illnesses or prescribed medications also associated with hyp onatraemia.
American Journal of Geriatric PsychiatryDouble-Blind, Randomized Comparison of Mirtazapine and Paroxetine in Elderly Depressed Patients
146 Citations2002Alan F. Schatzberg
International Clinical PsychopharmacologyEfficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder
145 Citations1999Esa Leìnonen, Jon Skarstein +3 more
Mirtazapine was significantly more effective than citalopram after 2 weeks of treatment on the MADRS, HAM-A and CGI Severity of illness and Quality of life scales, and was related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ.
American Journal of Geriatric PsychiatryA Double-Blind, Placebo-Controlled Study of Venlafaxine and Fluoxetine in Geriatric Outpatients With Major Depression
145 Citations2006Alan F. Schatzberg, Steven P. Roose
There was no significant difference in efficacy among placebo, venlafaxine, and fluoxetine for the treatment of depression in depressed patients older than 65 years.
The Journal of Clinical PsychiatryMirtazapine
145 Citations1998David P. Wheatley, Miriam van Moffaert +3 more
It was found that mirtazapine was as well tolerated as fluoxetine and significantly more effective after 3 and 4 weeks of therapy.
American Journal of Geriatric PsychiatryA Controlled Clinical Trial of Sertraline in the Treatment of Depression in Nursing Home Patients With Late-Stage Alzheimer's Disease
144 Citations2000Carol Magai, Gary J. Kennedy +2 more
A sample of 31 female nursing home patients with late-stage Alzheimer's disease participated in a double-blind clinical trial of the antidepressant medication sertraline, and the "knit-brow" facial measure approached significance for a Treatment x Time effect.
American Journal of PsychiatryFluoxetine Treatment for Depression in Patients With HIV and AIDS: A Randomized, Placebo-Controlled Trial
142 Citations1999Judith G. Rabkin, Glenn J. Wagner +1 more
Fluoxetine is an effective antidepressant in the context of HIV illness, however, both placebo response and attrition were substantial, suggesting both that nonspecific factors may be more salient and that yet another medication may be less acceptable among patients with serious medical illness already requiring multiple concomitant medications.
International PsychogeriatricsA Double-Blind, Placebo-Controlled Clinical Trial of Fluoxetine in Geriatric Patients With Major Depression
141 Citations1995Gary D. Tollefson, J C Bosomworth +3 more
Fluoxetine, at a conventional 20-mg dose, was both safe and effective relative to placebo in this special population of outpatients over age 60, corroborate that major depression in an older population is responsive to antidepressant pharmacotherapy.
International PsychogeriatricsA Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Patients With Alzheimer’s Disease
140 Citations2001Gustavo Petracca, Erán Chemerinski +1 more
Both the fluoxetine and the placebo groups showed a significant decline in HAM-D scores over time, but the magnitude of mood improvement was similar for both groups, confirming the presence of a placebo effect in the treatment of depression in AD.
Journal of Clinical PsychopharmacologyA Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder
140 Citations2005Maurizio Fava, Jonathan E. Alpert +6 more
St John's wort was significantly more effective than fluoxetine and showed a trend toward superiority over placebo and appeared to be safe and well tolerated.
…